Fundación Cori para la Investigación y Prevención del Cáncer - La Rioja

Dorrego 269, La Rioja

Select an option

I am a doctor

I am a sponsor

Our team

Medical staff

Brenda De la Vega

Diego Lucas Kaen

Matías Benzo

Romina Paredes

Viviana Paez

Harold Somerville

María Laura Luna

Luis Kaen

Juan Marcelo Muraro

Open studies

Breast Cancer

A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer) - heredERA - Hoffmann-La RocheSee more

A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer - EMBER-4 - Eli Lilly and CompanySee more

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer - ASCENT-03 - Gilead SciencesSee more

Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors - CDK4i - PfizerSee more

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy - INAVO121 - Hoffmann-La RocheSee more

A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer - Hoffmann-La RocheSee more

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) - PionERA - Hoffmann-La RocheSee more

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment - PfizerSee more

OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer - OPERA-01 - Olema Pharmaceuticals, Inc.See more

Lung cancer

A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) - B-FAST - Hoffmann-La RocheSee more

Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment - SAFFRON - AstraZenecaSee more

Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer - STAR-121 - Arcus Biosciences, Inc.See more

Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors - CDK4i - PfizerSee more

A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation - Krascendo 170 - Hoffmann-La RocheSee more

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) - CodeBreaK 202 - AmgenSee more

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) and Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) - Merck Sharp & Dohme LLCSee more

Esophageal cancer

A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin - CheckMate 648 - Ono Pharmaceutical Co. LtdSee more

Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer. - FORTITUDE-102 - AmgenSee more

Bladder Cancer

A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder - SunRISe-2 - Janssen Research & Development, LLCSee more

Cervical cancer

A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20) - MK-2870-020 - GOG FoundationSee more

Endometrial Cancer

Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005) - MK-2870-005 - GOG FoundationSee more

Gastric cancer

Gastroesophageal cancer

Head and neck cancer

A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 - AHEAD-MERIT - BioNTech SESee more

Liposarcoma

Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors - CDK4i - PfizerSee more

Prostate cancer

Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors - CDK4i - PfizerSee more

Solid tumors

Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors - CDK4i - PfizerSee more